Panel, Conference Presentation
Perfecting Precision Health: Personalizing Medicine for All
Milken InstituteJoseph Mocanu, Shiho Azuma, David Berry, Kuldeep Singh Rajput, Helmut M. Schuehsler, Edwin Morris, Helmut Schüssler
- Non-communicable chronic diseases are predicted to compound uniquely as lifespans extend, necessitating a shift from specialist-led models of care for slow-moving conditions to broader personalized medicine definitions that incorporate lifestyle factors like diet, exercise, and work environments.
- Healthcare delivery systems face significant disruption due to unsustainability; specifically, the Chinese market is described as facing economic strain from over 8 billion outpatient visits and misdiagnosis rates exceeding 30%, driving a pivot toward AI-driven platforms that aim to reduce consultation costs to single-digit RMB and increase processing volume to 60 times that of a typical offline hospital.
- Drug development timelines and costs are projected to decrease significantly, with estimates suggesting a reduction from 15 years and $3.5 billion to 7 years and $200 million per drug, while digital health technologies may shorten approval timelines from seven to eight years down to two or three years by utilizing patient-centric outcomes.
- The pharmaceutical industry is characterized by a negative growth expectation of 1.9% per year and earnings compression driven by ineffective mergers, creating a foundational opportunity for innovation where therapeutics are expected to be redefined from a "diagnostics by therapy" model to one that emphasizes better patient matching to reduce the 30-35% of costs incurred by incorrect initial drug prescriptions.
- Digital therapeutics and software are expected to synergize with pharmacotherapy to optimize treatment for complex conditions, with platforms aiming to predict heart failure exacerbation at least two weeks in advance to potentially achieve a 68% reduction in hospitalization and mortality costs, while targeting the optimization of therapy for the less than 1% of patients currently on optimal dosages.
- Societal and regulatory frameworks are expected to transform over the next 10 to 20 years, addressing challenges related to data privacy, insurance solidarity, and the potential for mass customization of drugs, alongside expectations that government policy will increasingly include internet healthcare in social insurance and that insurance models will adapt to data-driven risk predictions.
- Investment and market confidence are anticipated to align with the vision of democratizing healthcare through technology, with specific plans to launch AI diagnostic systems for breast cancer, establish dedicated family doctors accessible via mobile apps, and create personalized health management plans designed to prevent preventable diseases.
- Key risks and challenges include the regulatory industry's conservative approach to safety, the commercial viability of models focused on keeping patients healthy rather than treating acute issues, and the difficulty in establishing trust regarding data transparency and the alignment of payer incentives with patient-specific clinical outcomes.